Home
CHUYÊN ĐỀ
Issue: Số 70 (2015)
Article
Phạm Mạnh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Published: July 1, 2015
Views: 160
References
1.
1. Lemesle, G., et al., Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Arch Cardiovasc Dis, 2008. 101(11-12): p. 769-77.
2.
2. Iakovou, I., et al., Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005. 293(17): p. 2126-30.
3.
3. Schatz, R.A., et al., Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation, 1991. 83(1): p. 148-61.
4.
4. Serruys, P.W., et al., Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med, 1991. 324(1): p. 13-7.
5.
5. Kastrati, A., et al., Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007. 356(10): p. 1030-9.
6.
6. Mauri, L., et al., Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med, 2007. 356(10): p. 1020-9.
7.
7. Ong, A.T., et al., Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol, 2005. 45(6): p. 947-53.
8.
8. Stone, G.W., et al., Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007. 356(10): p. 998-1008.
9.
9. Moses, J.W., et al., Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003. 349(14): p. 1315-23.
10.
10. Lagerqvist, b., et al., Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med, 2007. 356(10): p. 1009-19.
11.
11. De la Torre-Hernandez, J.M., et al., Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol, 2008. 51(10): p. 986-90.
12.
12. Daemen, J., et al., Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007. 369(9562): p. 667-78.
13.
13. Parodi, G., et al., Effectiveness of primary percutaneous coronary interventions for stent thrombosis.
14.
Am J Cardiol, 2009. 103(7): p. 913-6.
15.
14. Siller-Matula, J., et al., Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
16.
Thromb Haemost, 2007. 97(3): p. 385-93.
17.
15. Steinhubl, S.R., et al., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002. 288(19): p. 2411-20.
18.
16. Sibbing, d. and S. Massberg, Dual antiplatelet treatment after stenting: is longer better? Lancet, 2014. 384(9954): p. 1553-5.
19.
17. Investigators, C.-O., et al., Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
20.
N Engl J Med, 2010. 363(10): p. 930-42.
21.
18. Mehran, R., et al., Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, 2013. 382(9906): p. 1714-22.
22.
19. Brar, S.S., et al., Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol, 2011. 58(19): p. 1945-54.
23.
20. Price, M.J., et al., Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011. 305(11): p. 1097-105.
24.
21. Wiviott, S.d., et al., Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J, 2006. 152(4): p. 627-35.
25.
22. Preobrazhenskii, d.v., [Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study]. Kardiologiia, 2010. 50(1): p. 68.
26.
23. Steg, P.G., et al., Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation, 2013. 128(10): p. 1055-65.
27.
24. Gurbel, P.A., et al., Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET study. Circulation, 2009. 120(25): p. 2577-85.
28.
25. Montalescot, G. and A.W. van ‘t Hof, Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med, 2014. 371(24): p. 2339.